Development and therapeutic evaluation of 5D3(CC-MLN8237)3.2 antibody-theranostic conjugates for PSMA-positive prostate cancer therapy

• Auteurs principaux: Ioanna Liatsou (Auteur), Betelhem Assefa (Auteur), Wathsala Liyanage (Auteur), Sharmane Surasinghe (Auteur), Zora Nováková (Auteur), Cyril Bařinka (Auteur), Kathleen Gabrielson (Auteur), Venu Raman (Auteur), Dmitri Artemov (Auteur), Sudath Hapuarachchige (Auteur)
• Format: Livre
• Publié: Frontiers Media S.A., 2024-05-01T00:00:00Z.
• Sujets: article
• Accès en ligne: Connect to this object online.

Prostate cancer (PC) is an aggressive cancer that can progress rapidly and eventually become castrate-resistant prostate cancer (CRPC). Stage IV metastatic castrate-resistant prostate cancer (mCRPC) is an incurable late-stage cancer type with a low 5-year overall survival rate. Targeted therapeutics...